CINQAIR® (Reslizumab)
Order Form


Important Safety Information

Cinqair (reslizumab) is a prescription infusion medication used to treat severe asthma in people who are 18 years of age or older, and for whom traditional medications have proven ineffective. It works by preventing asthma attacks and by making it easier to breathe, and it is used concurrently with other forms of treatment. However, it is possible for some patients to experience serious allergic reactions. Tell your doctor immediately if you experience a fast heart rate, hives, itching, swelling of your face, lips, or tongue, breathing difficulties, dizziness, confusion, abdominal pain, and/or nausea.

Cinqair may not mix well with other medications. Tell your doctor about all oral and inhaled drugs you are taking. Do not stop taking corticosteroids or any other asthma medications unless instructed by your healthcare professional. Also mention any prescription, over-the-counter, herbal supplements, and vitamins you are currently taking.

Prior to starting treatment, tell your doctor all details about your medical history. This is crucial for those who have or have had cancer or a parasitic infection.

It is not known whether Cinqair could harm an unborn baby or pass through your breast milk. Talk with your doctor if you’re pregnant, planning on becoming pregnant, or breastfeeding.

What is the most important information I should know about Cinqair?

Prior to starting treatment, describe to your doctor all details of your asthma attacks — how often they occur, how often you use your rescue inhaler, lung function test results, eosinophil levels, and how the condition affects your everyday life. Cinqair is not meant to be used for all types of asthma or in children. Do not use Cinqair to treat an initial asthma attack or for mild asthma. It should also not be used to treat acute asthma symptoms.

During clinical studies, malignancies were reported in a small number of patients. The majority of them were diagnosed within less than six months after starting treatment.

While there isn’t enough information about how Cinqair may affect an unborn baby, monoclonal antibodies — such as reslizumab — are transported across the placenta as a pregnancy advances. Therefore, there may be a risk of effects on the fetus during the second or third trimester.

Side Effects of Cinqair

As with any prescription medication, Cinqair carries the risk of side effects. The most common ones reported by patients include:

  • Mouth pain
  • Throat pain
  • Coughing
  • Dizziness
  • Difficulty swallowing
  • Tight sensation in the chest
  • Fast heartbeat

Tell your doctor if you experience any negative side effects. You are also encouraged to report such side effects to the Food and Drug Administration (FDA) by visiting, or by calling 1-800-FDA-1088.


Cinqair is usually administered once every four weeks for a duration between 20 and 50 minutes. The recommended dose is 3mg/kg.

Please refer to the full prescribing information.